REPLY
18.5.2021 09:32:11 CEST | Business Wire | Press release
Through its proprietary Trend Sonar trend monitoring platform, Reply recently conducted a study to examine how the e-commerce model has evolved over time – particularly in the automotive domain – revolutionising the sector and consequently influencing customer expectations.
A digital approach and a strong online presence have become indispensable in the automotive sector, especially since last year when the global pandemic placed the digital realm in a preferential lane, rewarding businesses that have been able to change their business model quickly in favour of digitisation.
Over the past year (more specifically from April 2020 to March 2021), analysing the frequency of mentions of millions of online sources – expert media articles, mass media, patents and scientific publications – Reply’s Trend Sonar monitoring platform has, indeed, confirmed a 61% growth in content related to automotive e-commerce compared to the previous 12 months.
An evolution that starts from afar. The automotive sector is not new to change: in the last 20 years it has been the protagonist of an unprecedented revolution. Reply’s analysis, in fact, shows that all the conditions and prerequisites are in place for the sector to find itself on the threshold of a new discontinuity.
The first online marketplaces for used cars date back to 2000, while a few years later the first online broker platforms began gaining popularity, directly connecting authorised dealers and end consumers and offering online booking, car configuration and digital brochure services. This was followed by the first online dealerships and, in recent years, car manufacturers have started selling their vehicles directly to the end consumer, adopting Direct to Consumer models.
Today's scenario: between the physical and the digital worlds. With the Covid-19 pandemic, the pace of digitalisation has greatly accelerated: digitised analytics systems, pricing tools and financing processes are now a necessary standard to help increase leads in the sector. Reply’s study highlights precisely how, at this point in time, we find ourselves at a crossroads between the offer of digital and traditional services. Indeed, in the near future, services such as 3D showrooms, virtual test drives, advanced configuration tools and digital concierge services are expected to see increasing use, allowing consumers to test and configure products directly online.
By opting for direct online sales to customers, native digital car manufacturers are turning the traditional car buying model upside down. The customer journey has also been impacted by the current revolution underway: leasing, financing, choice of insurance providers and coverage or even vehicle registration have recently digitised and automated the customer experience, shortening waiting times and eliminating paper documents.
The future of mobility is increasingly more virtual. Since car sharing services have entered the market, mobility has, in fact, begun to be perceived as a service built around the digital world . Many car manufacturers and industry suppliers are adopting an approach in which the car is becoming a platform capable of providing access to a broad digital ecosystem of app-based data and services. In fact, in the future, in addition to a means of mobility and transport, cars are expected to be increasingly used as a tool to collect data on customers. Access, exchange and sharing of this information will be decisive for defining future dynamics and for offering the customer a range of more complete and personalised services, which may even include solutions proposed by customers themselves.
More information on the research is available on Reply’s website at “E-commerce trends: mobility and car sales ”.
Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210518005081/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
